Introduction:-Rodenticide is one of the pesticides and heterogeneous substances used to kill rats. Rodenticide poisoning is a major health problem in Asian countries, particularly the mode of self-poisoning, prevalent in India. It causes hepatotoxicity and no antidote has been found. N-acetylcysteine (NAC) is a powerful antioxidant and used in the treatment of acetaminophen-induced hepatotoxicity. The main objectives of this study were to determine the role of NAC in liver impairment rodenticide poisoning patients. Methods:-Patients who ingested rat killer poison and age >15 years were included in the study. Patients having jaundice, liver disease, and age <15 years were excluded from the study. Results:-Out of 50 patients. 27 (54%) were females and 23 (46%) were males. Age group between 21-30 years contributes the highest 20 (40%). The majority of types of rodenticide compounds consumed by patients were paste 29 (58%) and less than four hours 26 (52%) patients were admitted. and 7 (14%) patients died. Conclusion:-In liver impairment rodenticide poisoning patients, early use of NAC shows a significant result and the rate of recovery is also high.
This study aims to present the clinical results of patients administered rivaroxaban for the treatment of deep vein thrombosis (DVT) in terms of efficacy and safety. Methods: A total of 50 patients (30 males, 20 females age range 25 to 88 years) diagnosed with DVT had received rivaroxaban treatment in the department of medicine, Chhattisgarh Institute of Medical Science (CIMS) Bilaspur Chhattisgarh India. between September 2018 and august 2020 were included in the study. Deep vein thrombosis diagnoses of the patients were confirmed by Doppler ultrasonography. The patients' epidemiological and biochemical values were evaluated. Major-minor bleeding and recurrence that occurred during rivaroxaban treatment was investigated. Results: Patients were treated for 3, 6 or 12, months, according to flow up and result. When anticoagulant treatments of the patients were examined, 15 patients (30%) were treated with rivaroxaban as initial treatment and 35 patients (70%) had transitioned from warfarin to rivaroxaban treatment. In patients using rivaroxaban, one patient had hypermenorrhea and two patients had epistaxis. Major bleeding was not detected. While three patients had alanine aminotransferase levels up to two times higher than the normal limit, none of the patients had clinically significant liver or kidney failure. Recurrent DVT or pulmonary embolism was not detected in the patients. Conclusion: According to the current guidelines and literature findings novel oral anticoagulants could be used safely and efficiently as a first line drug therapy in DVT patients due to their non-inferior effectiveness to warfarin and lower side effect profile.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.